Objective. To quantify the prevalence of potential drug-drug/drug-condition interactions (DDI/DCI) among fibromyalgia patients initiating pregabalin or duloxetine, and to determine the impact of potential DDI/DCI on health care expenditures. Results. Seven thousand seven hundred fifty-one pregabalin and 7,785 duloxetine initiators were selected for study: mean age 49 years, 88% female. Only 1.4% of pregabalin initiators had ≥1 potential pregabalin DCI; none had potential pregabalin DDI. In contrast, 67% of duloxetine initiators had potential duloxetine DDI/DCI, driven mostly by potential duloxetine DDI (62% of duloxetine initiators). Compared between pregabalin and duloxetine initiators, differences in the prevalence of potential DDI/DCI were statistically significant (P < 0.001). Multivariable analyses indicated that, among duloxetine initiators, those with potential duloxetine DDI/DCI had postinitiation health care expenditures that were $670 higher (P < 0.001) than those without potential duloxetine DDI/DCI. Among pregabalin initiators, potential pregabalin DDI/DCI were not associated with health care expenditures.
Introduction
Fibromyalgia is a syndrome characterized principally by chronic, widespread musculoskeletal pain and tenderness [1] . The prevalence rate of fibromyalgia has been estimated at approximately 2% in the United States, with women being nearly seven times more likely to have the condition than men [2] . In addition to pain, fibromyalgia is associated with a constellation of symptoms and comorbidities, and is therefore often treated through multimodal approaches, including both pharmacological and nonpharmacological strategies [3] .
Because of the complexities of comorbidity and polypharmacy that are inherent to the nature of fibromyalgia and its management, patents with fibromyalgia can be placed at increased risk for drug-drug and drug-condition interactions (DDI/DCI). Such interactions can present significant challenges to the choice of appropriate fibromyalgia medication. Indeed, the most recent published treatment guidelines for fibromyalgia-the 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome-emphasize importance of vigilance with respect to side effects and DDI, particularly in the context of polypharmacy [3] . Furthermore, the presence of comorbidities in a patient often necessitates that concomitant medications be prescribed to manage the comorbidity, thereby presenting not only potential DCI risks, but also DDI risks. Thus, both DDI and DCI must be considered when choosing a medication that is safest for a given patient.
In the United States, pregabalin (an anticonvulsant), duloxetine (a serotonin-norepinephrine reuptake inhibitor), and milnacipran (a serotonin-norepinephrine reuptake inhibitor) are currently approved by the Food and Drug Administration for treatment of fibromyalgia [4] [5] [6] . Among these three medications, pregabalin and duloxetine are presently the two that are most often used among patients with fibromyalgia [7] . Pregabalin differs from duloxetine in terms of its risk for potential DDI and the medical conditions with which it may cause DCI: because pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans, and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement [4] . In contrast, however, because duloxetine undergoes hepatic metabolism via CYP2D6 and CYP1A2, is an inhibitor of CYP2D6 and CYP1A2, and is highly bound to plasma protein, there are many medications that carry the risk for potential DDI with duloxetine [5] . DDI/DCI have led to increased health care utilization and expenditures in a variety of clinical settings [8] [9] [10] [11] [12] [13] . No published studies have focused on DDI/DCI among fibromyalgia patients who are being treated with pregabalin or duloxetine. Accordingly, the overall objective of this study was to examine the prevalence and health care expenditure impact of potential DDI/DCI in fibromyalgia patients initiating pregabalin or duloxetine.
This study had four sets of specific research objectives, specified in advance. The primary research objectives were to 1) quantify and compare the prevalence of potential duloxetine and pregabalin DDI/DCI; 2) to quantify (a) the impact of potential pregabalin DDI/DCI on postinitiation health care expenditures in pregabalin initiators and (b) the impact of potential duloxetine DDI/DCI on postinitiation health care expenditures in duloxetine initiators; and 3) to compare the postinitiation health care expenditures of (a) pregabalin initiators with potential pregabalin DDI/DCI vs (b) duloxetine initiators with potential duloxetine DDI/DCI. The secondary research objective, which was the fourth overall objective, was to compare the postinitiation health care expenditures of 1) pregabalin initiators without pregabalin DDI/DCI but with duloxetine DDI/DCI vs 2) duloxetine initiators without pregabalin DDI/DCI but with duloxetine DDI/DC. This secondary research objective was included to examine the hypothetical expenditure impact of switching a duloxetine initiator without pregabalin DDI/DCI, but with duloxetine DDI/DCI to pregabalin.
Please note that milnacipran was not included for study because its use rates, which are comparatively lower than that for pregabalin and duloxetine, would not have yielded a sufficient sample size for analysis.
Methods

Design
This was a retrospective observational cohort study.
Setting and Data
The setting of this study was routine U.S. clinical practice, as reflected by administrative claims data contained in the Truven Health MarketScan® Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare Supplemental) databases.
These Commercial and Medicare Supplemental databases comprise inpatient and outpatient medical and outpatient prescription drug claims for employees, dependents, and retirees with employer-sponsored primary or Medicare supplemental insurance. Annually, approximately 30 million individuals are represented in these databases. Data corresponded to the period July 1, 2007 to March 31, 2011, and were the most recent data available within the MarketScan databases when this study was conducted. Individuals within the Commercial and Medicare Supplemental databases are covered under a variety of health plan types, including fee-for-service and managed care plans, among others. Payments from both Medicare and Medicare supplemental health insurance plans are included within the Medicare Supplemental database.
The data contained in these databases are statistically de-identified and have been certified to satisfy the conditions set forth in Sections 164.514 (a)-(b)1ii of the Health Insurance Portability and Accountability Act. As such, Institutional Review Board approval and written informed consent were not sought for this study.
Subjects
To be eligible for this study, subjects (patients) were required to meet the following inclusion criteria: had ≥1 outpatient prescription claim for pregabalin or duloxetine during the period July 1, 2008 to October 1, 2010 (the date corresponding to the first of such prescription claim during this period was set as the index date); did not have simultaneous prescription claims for both pregabalin and duloxetine on the index date; were aged 18 years or older on the index date; were continuously enrolled in medical and prescription insurance benefits for 12 months before (preperiod) and 6 months after (postperiod) the index date; and had ≥1 inpatient or ≥2 outpatient medical claims (excluding laboratory or radiology claims) with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code for fibromyalgia (729.1x) during the preperiod and postperiod. To increase the likelihood that pregabalin and duloxetine were prescribed for treatment of fibromyalgia, at least one of the medical claims with an ICD-9-CM diagnosis code for fibromyalgia was required to occur on the index date or within 60 days before the index date.
Patients were deemed ineligible for study if they met any of the following exclusion criteria were: patient was not a new initiator of pregabalin or duloxetine, as evidenced by ≥1 outpatient prescription claim for pregabalin or duloxetine during the preperiod; had evidence, during the preperod or postperiod, of medical conditions other than fibromyalgia in which pregabalin or duloxetine are indicated, or medical conditions or circumstances that may complicate measurement of variables, including: ≥1 medical claim with an ICD-9-CM diagnosis code for postherpetic neuralgia (053.1x) or epilepsy (345.xx, 780.39); ≥1 medical claim with an ICD-9-CM or Current Procedural Terminology (CPT-4®) procedure code (available upon request) for transplant surgery; ≥1 inpatient or ≥2 outpatient (on different days, at least 21 days apart) medical claims with an ICD-9-CM diagnosis code for cancer (140.xx-172.xx, 174.xx-208.xx, 235.xx-239.xx) with the exception of basal cell and squamous cell skin cancers and benign neoplasms; or residence in a long-term care facility for ≥90 total days.
Potential DDI Measurement
Clinical practice medication management software (MicroMedex® DRUG-REAX®, Truven Health Analytics, Ann Arbor, MI, USA) was used to measure potential DDI [14] . The DRUG-REAX software was used to analyze patients' prescription claims to identify coprescription of medications that potentially interact with pregabalin or duloxetine. The DRUG-REAX software's compendium of potential DDIs is based on continual scientific literature and drug label review. The DRUG-REAX software is one of the most widely employed medication management software systems in the United States.
Prescription claims that were filled within 180 days before to 30 days after the index date and that had days supply extending beyond the index date (to ensure close temporal proximity in possession of pregabalin/duloxetine and potentially interacting medications) were analyzed for potential interactions with pregabalin and duloxetine. If a prescription that met these criteria was identified as having the potential to interact with pregabalin or duloxetine, the DRUG-REAX software then ranked the potential DDI according to four levels of severity: 1) contraindicated-medications are contraindicated for concurrent use; 2) major-the interaction may be life threatening and/or require medical intervention to minimize or prevent serious adverse effects; 3) moderate-the interaction may result in an exacerbation of the patient's condition and/or require a modification of therapy; and 4) minor/no potential-the interaction would have limited or no clinical effects, manifestations may include an increase in the frequency or severity of side effects but generally would not require a major alteration in therapy.
Because potential for minor interactions may not be clinically meaningful in routine clinical practice, potential DDI were flagged for study only if they carried contraindicated, major, or moderate severity ratings. Furthermore, the DRUG-REAX software also indicates an "evidence rating" for each potential DDI, and based on this information potential DDI were flagged for study only if they were listed within the pregabalin or duloxetine prescribing information or carried a "good" or "excellent" evidence rating.
Potential DCI Measurement
Potential DCI were measured using administrative claimsbased algorithms to identify, during the 12-month preindex period, the presence of medical conditions listed in the contraindications and warnings and precautions sections of pregabalin and duloxetine prescribing information. Also included for both medications was pregnancy, which is listed under use in specific populations. Nosologists (professionals specializing in disease classification and coding) assisted in assigning each DCI an administrative claims-based identification algorithm. The detailed criteria used for the administrative claims-based identification algorithms are provided in the Appendix.
Potential DCI were not included for study if administrative claims data could not be used to measure them (e.g., tumorigenic potential [pregabalin]), if there were no known factors that influence heterogeneity in the risk of interaction (e.g., weight gain [pregabalin]), or if they were not thought to affect clinical decision making in the context of prescribing medication to fibromyalgia patients (e.g., glycemic control in patients with diabetes [duloxetine]). The potential DCI that were not included for study are provided in the Appendix.
Health Care Expenditures, Demographics, and Clinical Characteristics Measurement
All-cause health care expenditures were measured throughout the 6-month postindex period. A 6-month period was chosen to measure health care expenditures to ensure that expenditures were for use of health care services that were close to the index date in temporal proximity. Health care expenditures corresponded to the sum of gross covered payments for all medical and prescription claims and were normalized to 2011 constant dollars using the Consumer Price Index medical care component [15] .
Enrolment data were used to measure demographic characteristics such as age and sex as of the index date. Inpatient and outpatient medical, and outpatient pharmaceutical claims data were used to measure clinical characteristics such as preindex comorbidities and medications based on ICD-9-CM codes, CPT-4 codes, Healthcare Common Procedure Coding System codes, and National Drug Codes present during the preperiod. Clinical characteristics were drawn from previously published chronic pain studies that used administrative claims and involved pregabalin and duloxetine [16] [17] [18] .
Statistical Analyses
Univariate, bivariate, and multivariable statistical approaches were employed for analysis. Within-group prevalence rates (e.g., prevalence of potential pregabalin DDI/DCI in pregabalin initiators) were analyzed using univariate statistical analyses. The statistical significance of differences in the prevalence of potential DDI/DCI across groups was determined through chi-squared tests. The statistical significance of differences in the 6-month postinitiation mean all-cause health care expenditures between selected groups of patients was determined through multivariable models. Specifically, multivariable modeling was conducted through generalized linear models with a log link and gamma error distribution [19, 20] . Multivariable log-linear (i.e., taking the natural logarithm of the expenditure outcome) ordinary least squares (OLS) models were used for cases in which kurtosis with respect to log scale residuals for the expenditure distribution was greater than 3 [19, 21] . These models adjusted for all measured patient demographics and clinical characteristics, which are listed in Table 1 . When retransforming expenditures to the dollar scale for the log-linear OLS models, a "smearing" factor was applied [22] . A P ≤ 0.05 was set as the a priori threshold for statistical significance on inference related to the study hypotheses. The recycled prediction method [23] was used to generate predicted mean expenditure differences between selected groups of patients. Statistical Analysis Software (SAS) 9.2 (SAS Institute Inc., Cary, NC, USA) was used for data management. Stata/MP 10 (StataCorp, College Station, TX, USA) was used for multivariable analyses.
Results
Patients
The sample attrition resulting from application of each study selection criterion is presented in Figure 1 . Ultimately, 7,751 pregabalin and 7,785 duloxetine initiators were selected for study.
Patients' demographics and preperiod clinical characteristics are presented in Table 1 , with pregabalin and duloxetine initiators stratified by presence or absence of potential DDI/DCI for their initiated drug.
Within the stratifications, pregabalin initiators' preindex comorbidity indices-such as the Deyo-Charlson Comorbidity Index, number of unique medications, and number of unique three-digit ICD-9-CM diagnosis codes-had per-patient mean values that indicated that these patients had poorer general health than duloxetine initiators. For example, while pregabalin initiators with potential pregabalin DDI/DCI had an average of 24.7 unique three-digit ICD-9-CM diagnosis codes (standard deviation [SD] = 11.5), duloxetine initiators with potential duloxetine DDI/DCI had an average of 16.6 (SD = 9.1).
Potential DDI/DCI Prevalence
The prevalence rates of potential DDI/DCI, stratified by medication initiated, are presented in Figure 2 . Approximately 1% (107 patients) of the 7,751 pregabalin initiators had potential pregabalin DCI; none had potential pregabalin DDI. In contrast, 67% (5,184 patients) of the 7,785 duloxetine initiators had potential duloxetine DDI/ DCI. The prevalence of potential duloxetine DDI/DCI among duloxetine initiators was largely driven by potential duloxetine DDI, with 62% (4,819 patients) having a potential duloxetine DDI and 14% (1,067 patients) having potential duloxetine DCI.
The prevalence rates of individual potential DDI/DCI for pregabalin initiators and duloxetine initiators are presented in Tables 2 and 3 , respectively. Dizziness was the most common individual potential pregabalin DCI among pregabalin initiators, occurring in approximately 1% (70 patients) of the 7,751 pregabalin initiators. Potential for major duloxetine DDI was the most common individual potential duloxetine DDI/DCI among duloxetine initiators, occurring in 45% (3,478 patients) of the 7,785 duloxetine initiators. Furthermore, potential major duloxetine DDI most frequently involved amitriptyline, which was identified in 16% of all potential major duloxetine DDI.
Potential duloxetine DDI/DCI were present in 83% (89 patients) of the 107 pregabalin initiators with pregabalin DDI/DCI. Potential pregabalin DDI/DCI were present in approximately 2% (92 patients) of the 5,185 duloxetine initiators with duloxetine DDI/DCI.
Expenditure Impact of Potential DDI/DCI
Results of the multivariable analyses quantifying various aspects of the health care expenditure impact of potential pregabalin and duloxetine DDI/DCI on postinitiation health care expenditures in pregabalin and duloxetine initiators are presented in Table 4 . Potential pregabalin DDI/DCI did not have a statistically significant impact (P = 0.732) on postinitiation health care expenditures in pregabalin initiators. However, potential duloxetine DDI/DCI were associated with a $670 (P < 0.001) increase in postinitiation P value corresponds to the statistical significance of differences between two adjacent columns to the left of the P value column; * indicates that P health care expenditures in duloxetine initiators. The postinitiation health care expenditures of pregabalin initiators with potential pregabalin DDI/DCI were not significantly different (P = 0.362) from those of duloxetine initiators with potential duloxetine DDI/DCI. Finally, the postinitiation health care expenditures of pregabalin initiators without pregabalin DDI/DCI but with duloxetine DDI/ DCI were $855 (P = 0.002) higher than those of duloxetine initiators without pregabalin DDI/DCI but with duloxetine DDI/DCI.
Discussion
This is the first study to quantify, empirically, the prevalence and impact on health care expenditures of potential pregabalin and duloxetine DDI/DCI among fibromyalgia patients initiating pregabalin or duloxetine.
Because of its pharmacokinetic profile, pregabalin differs from duloxetine in terms of its risk for potential DDI and the medical conditions with which it may cause DCI [4, 5] . These differences were not only confirmed, but also quantified in the present study's findings, which indicated that while approximately 1% of pregabalin initiators had potential pregabalin DCI, 67% of duloxetine initiators had potential duloxetine DDI/DCI. These differences were primarily driven by a high prevalence of potential duloxetine DDI and a complete absence of potential pregabalin DDI. Although pregabalin's pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement, there are many medications that carry the risk for potential DDI with duloxetine [4, 5] . Thus, these findings of large differences in the prevalence of potential DDI are not surprising.
Prior studies examining subjects similar to the one examined in the present study are limited; however, results from two studies corroborate the present study's findings. In the first study, Sadosky et al. studied administrative claims from U.S. fibromyalgia patients and found that the number of patients with comorbidities or medications that might render them potentially inappropriate candidates for duloxetine was four times greater than that for pregabalin [24] . In the second study, which was reported by the Institute for Safe Medication Practices, duloxetine was ranked the eighth most frequently suspected medication in reports of serious adverse drug events submitted by health professionals and patients directly to the U.S. Food and Drug Administration in 2011 [25] .
Although the presence of potential pregabalin DDI/DCI was not significantly associated with health care expenditures in pregabalin initiators in the present study, the presence of potential duloxetine DDI/DCI was significantly associated with increased health care expenditures in duloxetine initiators. While this study did not attempt to elucidate the reason for these findings, which would be worthwhile to investigate in future research, three prior pain-focused studies related to the expenditure implications of DDI found that DDI were associated with increases in health care expenditures. Specifically, these studies found that potential DDI between opioid analgesics and medications that are metabolized through the CYP450 system were associated with increases in health care expenditures that ranged from $667 in moderate to severe chronic noncancer pain patients to $1,207 in osteoarthritis patients over a 6-month period after exposures to potential DDI [26] [27] [28] . Future research examining the magnitude of health care expenditure impact resulting from DDI between specified individual drugs could inform prescribers about which potential DDI should be afforded the most attention.
The present study's secondary research objective was included to examine the hypothetical expenditure impact of switching a duloxetine initiator without pregabalin DDI/ DCI but with duloxetine DDI/DCI to pregabalin. The finding related to the secondary research objective was that the postinitiation health care expenditures of pregabalin initiators without pregabalin DDI/DCI but with duloxetine DDI/ DCI were $855 (P = 0.002) higher than those of duloxetine initiators without pregabalin DDI/DCI but with duloxetine DDI/DCI. While this finding was unexpected, it must be considered in the context of the observational nature of the study; patients were not actually switched from duloxetine to pregabalin, and pregabalin may generally be prescribed to patients who are systematically different from those to whom duloxetine is prescribed.
This study had limitations. Because this study quantified only the prevalence of potential DDI/DCI, it is unknown whether a DDI/DCI actually occurred. Concomitantly prescribed potentially interacting medications analyzed by the DRUG-REAX software were filled in close temporal proximity to the index date; however, one medication could have been discontinued prior to the initiation of the other. Thus, it is unknown whether potentially interacting medications were actually taken concomitantly. Because the DRUG-REAX software does not identify additive adverse effects, which are clinically distinct from DDI, they were not included for study. Concomitant use of pregabalin and angiotensin converting enzyme inhibitors (a subclass of antihypertensive medications, for which there are possible additive adverse effects with duloxetine), pregabalin and central nervous system (CNS) depressants (a subclass of CNS acting medications, for which there are possible additive adverse effects with duloxetine), and pregabalin and thiazolidinediones may cause additive adverse effects.
Nonetheless, the clinical insights that can be gained from information on the prevalence of potential additive adverse effects are highly limited by the broad nature of these additive adverse effect-related medications Table 1 displays the patients characteristics used as covariates within the multivariable models; expenditure ratios are interpreted as the mean expenditures in a given group divided by those in reference group (e.g., an expenditure ratio of 1.030 indicates that the given group's expenditures are 3.0% higher than the reference group's expenditures). The recycled prediction method was used to generate predicted mean expenditure differences between selected groups of patients. When retransforming expenditures to the dollar scale for the log-linear OLS models, a "smearing" factor was applied [22] . CI = confidence interval from multivariable model; DCI = drug-condition interaction; DDI = drug-drug interaction; GLM = generalized linear model; OLS = ordinary least squares; SD = standard deviation.
classes. Post hoc analyses found that 92.4% of pregabalin initiators and 89.1% of duloxetine initiators had at least one potential duloxetine CNS additive adverse effect or DDI.
Furthermore, there is suboptimal sensitivity for the administrative claims-based identification algorithms used to identify undercoded potential DCI, such as suicide and alcohol use. Potential DCI for which there are no ICD-9-CM diagnosis codes, including tumorigenic potential (pregabalin), PR interval prolongation (pregabalin), and uncontrolled narrow-angle glaucoma (duloxetine), could not be measured using the data source in this study. In addition, because the databases used for this study are nonprobability samples, results may not be generalizable to the entire U.S. population.
Finally, this study did not include milnacipran, which like duloxetine is a serotonin-norepinephrine reuptake inhibitor and is now currently approved by the Food and Drug Administration for treatment of fibromyalgia. Milnacipran was not included for study because its use rates, which are comparatively lower than that for pregabalin and duloxetine, would not have yielded a sufficient sample size for analysis [7] .
In spite of any of these limitations, we do not believe that they would materially alter the results and the conclusions of this study, or its clinical significance.
Clinical Significance
These findings underscore guideline recommendations that physicians should be vigilant with respect to DDI in fibromyalgia patients [3] . The polypharmacy and comorbidity that are inherent to the nature of fibromyalgia and its management tend to place patients at substantially greater risk for DDI/DCI related to duloxetine than for DDI/DCI related to pregabalin. Approaches that reduce coprescription of potentially interacting medications may be beneficial to inform physician choice of fibromyalgia medication and may ultimately benefit patients. Cautious prescribing is particularly warranted among older patients, as they can experience pharmacokinetic and pharmacodynamic changes that increase their risk of DDI and adverse events [29] .
Conclusion
Among fibromyalgia patients initiating pregabalin or duloxetine, potential duloxetine DDI could be highly prevalent. Among duloxetine initiators, potential duloxetine DDI/ DCI were significantly associated with increased health care expenditures. Not thought to affect the decision to prescribe a medication in fibromyalgia patients 5.9 Tumorigenic potential Not possible to measure tumorigenic potential in administrative claims data; not thought to affect the decision to prescribe a medication 5.10 Ophthalmological effects Not thought to affect the decision to prescribe a medication in fibromyalgia patients 5.11 Creatine kinase elevations Not thought to affect the decision to prescribe a medication in fibromyalgia patients
Decreased platelet count
≥2 medical claims, at least 30 days apart, with an ICD-9-CM diagnosis code for primary thrombocytopenia (287.3x), secondary thrombocytopenia (287.4x), or thrombocytopenia, unspecified (287.5x); measured during preperiod 5.13 PR interval prolongation Not possible to measure PR interval prolongation in administrative claims data; not thought to affect the decision to prescribe a medication Duloxetine/pregabalin Pregnancy category C ≥1 medical claim with an ICD-9-CM procedure code for birth-related procedures (72.xx, 73.xx, 74.xx) or with a CPT procedure code for birth-related procedures (59050, 59051, 59300, 59400, 59409, 59410, 59414, 59430, 59510, 59514, 59515, 59525, 59610, 59612, 59614, 59618, 59620, 59622, 59898, 59899); measured during postperiod CPT-4 = Current Procedural Terminology; DCI = drug-condition interaction; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.
